US 12194079
Therapeutic regimen for the treatment of Fabry using stabilized alpha-galactosidase
granted A61KA61K38/47A61P
Quick answer
US patent 12194079 (Therapeutic regimen for the treatment of Fabry using stabilized alpha-galactosidase) held by Protalix Ltd. expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Protalix Ltd.
- Grant date
- Tue Jan 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 6
- CPC classes
- A61K, A61K38/47, A61P, A61P3/00, A61P43/00